We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-4.93%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$98.8B
AUM Growth
-$3.4B
Cap. Flow
+$2.69B
Cap. Flow %
2.72%
Top 10 Hldgs %
24.29%
Holding
4,219
New
200
Increased
1,781
Reduced
1,776
Closed
283
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PRU icon
426
Prudential Financial
PRU
$42.2B
$33.1M 0.03%
386,122
+5,261
+1% +$506K
HCA icon
427
HCA Healthcare
HCA
$88.8B
$33M 0.03%
179,498
-3,299
-2% -$657K
VFH icon
428
Vanguard Financials ETF
VFH
$13.8B
$32.8M 0.03%
440,597
+31,114
+8% +$2.53M
ECL icon
429
Ecolab
ECL
$79.8B
$32.5M 0.03%
224,833
-26,868
-11% -$4.36M
FDN icon
430
First Trust Dow Jones Internet Index Fund ETF
FDN
$5.38B
$32.5M 0.03%
257,172
-21,926
-8% -$3.05M
RBC icon
431
RBC Bearings
RBC
$17.7B
$32.2M 0.03%
154,713
+44,211
+40% +$10.2M
HSY icon
432
Hershey
HSY
$36.4B
$32M 0.03%
145,049
-4,581
-3% -$1.03M
CGDV icon
433
Capital Group Dividend Value ETF
CGDV
$38.8B
$32M 0.03%
1,565,260
+1,513,265
+2,910% +$34.4M
IWO icon
434
iShares Russell 2000 Growth ETF
IWO
$14.9B
$31.9M 0.03%
154,362
+3,199
+2% +$720K
VTIP icon
435
Vanguard Short-Term Inflation-Protected Securities Index Fund
VTIP
$19.8B
$31.7M 0.03%
659,553
-37,911
-5% -$1.88M
GSK icon
436
GSK
GSK
$103B
$31.6M 0.03%
1,074,160
-127,163
-11% -$4.82M
CTRA
437
DELISTED
Coterra Energy
CTRA
$31.3M 0.03%
1,199,865
-77,295
-6% -$2.21M
VMC icon
438
Vulcan Materials
VMC
$37.2B
$31.1M 0.03%
197,317
-24,653
-11% -$4M
MCO icon
439
Moody's
MCO
$82.6B
$31.1M 0.03%
127,864
+11,778
+10% +$3.42M
MKTX icon
440
MarketAxess Holdings
MKTX
$5.72B
$31M 0.03%
139,500
-1,755
-1% -$450K
CDW icon
441
CDW
CDW
$17B
$30.8M 0.03%
197,612
-31,633
-14% -$5.42M
FNF icon
442
Fidelity National Financial
FNF
$13B
$30.8M 0.03%
885,792
-85,419
-9% -$3.19M
EEM icon
443
iShares MSCI Emerging Markets ETF
EEM
$29.9B
$30.8M 0.03%
883,842
-139,404
-14% -$5.44M
SNPS icon
444
Synopsys
SNPS
$78.3B
$30.8M 0.03%
100,819
-1,325
-1% -$449K
AMCR icon
445
Amcor
AMCR
$21.8B
$30.8M 0.03%
573,871
+147,209
+35% +$9.03M
ESGU icon
446
iShares ESG Aware MSCI USA ETF
ESGU
$18.3B
$30.7M 0.03%
386,468
-5,638
-1% -$499K
FLOT icon
447
iShares Floating Rate Bond ETF
FLOT
$10.5B
$30.4M 0.03%
605,379
+25,486
+4% +$1.28M
SNY icon
448
Sanofi
SNY
$104B
$30.4M 0.03%
799,009
-155,147
-16% -$6.91M
EFX icon
449
Equifax
EFX
$21.3B
$30.3M 0.03%
176,957
+115,956
+190% +$22.7M
BCS icon
450
Barclays
BCS
$93.8B
$30.2M 0.03%
4,722,472
+130,785
+3% +$1.01M

Similar funds

Raymond James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Raymond James & Associates held 4,219 positions worth $98.8B, down 3.3% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2022 filing shows 200 new, 1,781 increased, 1,776 reduced and 283 closed positions. Its largest new stake was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M. The largest sale was iShares Core 1-5 Year USD Bond ETF, an estimated $255M.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

  • Raymond James & Associates's largest Q3 2022 buy was JPMorgan Nasdaq Equity Premium Income ETF: 332,653 shares worth $13.9M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q3 2022, an estimated $620M increase.
  • Raymond James & Associates's biggest Q3 2022 reduction was iShares Core 1-5 Year USD Bond ETF, cutting an estimated $255M.
  • Raymond James & Associates fully exited CDK Global, Inc. in Q3 2022, selling an estimated $36M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $98.8B portfolio in Q3 2022.
  • Raymond James & Associates opened 200 new positions and closed 283 in Q3 2022.
  • Raymond James & Associates's portfolio value fell 3.3% quarter-over-quarter to $98.8B.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.